Company intelligence / Profile preview
Noa Therapeutics
Toronto, Ontario, Canadanoatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing NOA-101, a non-steroidal lead drug compound that simultaneously addresses three constructive targets for atopic dermatitis. Currently working with external researchers and academic partners to validate therapeutic value in animal models to enable submission for clinical trials.
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Small moleculestrimodal therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Johnson & Johnson Innovation – JLABS (resident company)
Beyond the preview
Go deeper on Noa Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noa Therapeutics.